Mitochondrial DNA Damage and Inflammasome Activation in Vascular Inflammation

血管炎症中的线粒体 DNA 损伤和炎症小体激活

• 批准号: 8776918
• 负责人: Moshe Arditi
• 金额: $ 25.05万
• 依托单位: CEDARS-SINAI MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-12-01 至 2016-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8776918
• 关键词: 8-hydroxy-2' -deoxyguanosine; Address; Animal Model; Animals; Apoptosis; Arterial Fatty Streak; Atherosclerosis; Autophagocytosis; Binding; Cause of Death; Cell Proliferation; Cholesterol; Chronic; Clinical Research; Clinical Trials; Coronary Arteriosclerosis; Coronary artery; Coronary heart disease; Cytosol; DNA; DNA Damage; DNA Repair; Data; Development; Diet; Disease; Event; Fatty acid glycerol esters; Gene Transfer; Genes; Goals; Growth; Health; Human; Hypertrophy; Induction of Apoptosis; Inflammation; Inflammatory; Interleukin-1; Interleukin-18; Knowledge; Laboratories; Lead; Link; Low Density Lipoprotein oxidation; Mitochondria; Mitochondrial DNA; Mus; NF-kappa B; Non-Insulin-Dependent Diabetes Mellitus; Nucleosides; Outcome; Pathway interactions; Phase; Physiological; Play; Prevention; Process; Production; Reactive Oxygen Species; Role; Seminal; Signal Transduction; Stress; System; Therapeutic; Vasculitis; atherogenesis; base; cytokine; in vivo; macrophage; mitochondrial dysfunction; mouse model; novel; novel therapeutic intervention; overexpression; oxidant stress; oxidative DNA damage; oxidative damage; pre-clinical; prevent; repaired; treatment strategy; vascular inflammation

DESCRIPTION (provided by applicant): Atherosclerotic heart disease is the leading cause of death in the USA. Chronic inflammation is a key component of this process and manipulation of inflammation may yield novel treatments. Recent studies have highlighted IL-1beta, as a key inflammatory cytokine in chronic inflammation, including vasculitis and atherosclerosis, and clinical trials are underway to neutralize IL-1beta in type 2 diabetes and atherosclerosis. Previous studies showed a key role of IL-1beta and apoptosis in plaque progression, but no mechanistic connections were drawn between these two processes and the exact mechanism by which IL-1beta is activated was not known until now. We have recently discovered the elusive mechanism of NLRP3 inflammasome activation for IL-1beta production, and linked apoptosis and mitochondrial (Mt) oxidative DNA damage to this pathway. We showed that danger signals that induce Mt dysfunction and ROS in the Mt, result in damaged (oxidized) mtDNA that is released into the cytosol where it binds to and activates the NLRP3 inflammasome, the machinery by which active IL-1beta is made. Based on these recent seminal findings, the main goal of this exploratory R21 proposal is to investigate the role of mtDNA damage during apoptosis and induction of IL-1beta as it relates to vascular inflammation and atherosclerosis in order to find novel and more efficient ways to prevent and treat this disease. We will manipulate the mitochondrial DNA repair system to investigate its potential as a new treatment strategy that would prevent the activation of IL-1beta (as well as IL-18- the other NLRP3-dependent cytokine), as opposed to current strategies to neutralize IL-1beta after it is already released and led to downstream activation. Based upon these key findings, we propose the following two Aims focused around the central hypothesis that oxidative mtDNA damage that occurs during vascular inflammation activates the NLRP3 inflammasome for IL-1beta production and plays a proinflammatory role in atherogenesis. Inhibition of oxidative DNA damage will prevent NLRP3 inflammasome activation and result in decreased vascular inflammation and atherosclerosis. Specific AIM 1- To define the role of mitochondrial DNA damage during NLRP3 inflammasome activation in a diet-induced hypercholesterolemic mouse models of atherosclerosis using mice deficient in the DNA damage repair gene Ogg1.AIM 2- To investigate the therapeutic role of blocking mitochondrial DNA induced NLRP3 activation by synthetic 8-OH-dG administration and to determine the role of augmenting the Mt DNA repair with Ogg1 gene transfer.

描述（由申请人提供）：动脉粥样硬化性心脏病是美国的主要死因。慢性炎症是这一过程的关键组成部分，操纵炎症可能会产生新的治疗方法。最近的研究强调了IL-1 β作为慢性炎症（包括血管炎和动脉粥样硬化）中的关键炎症细胞因子，并且正在进行中和2型糖尿病和动脉粥样硬化中的IL-1 β的临床试验。以前的研究表明，IL-1 β和细胞凋亡在斑块进展中起着关键作用，但这两个过程之间没有机械联系，IL-1 β激活的确切机制至今仍不清楚。我们最近发现了NLRP 3炎性体激活IL-1 β产生的难以捉摸的机制，并将凋亡和线粒体（Mt）氧化DNA损伤与该途径联系起来。我们发现，诱导Mt功能障碍和Mt中的ROS的危险信号，导致受损（氧化）的mtDNA释放到细胞溶质中，在那里它结合并激活NLRP 3炎性小体，活性IL-1 β的机制。基于这些最新的开创性发现，这项探索性R21提案的主要目标是研究mtDNA损伤在细胞凋亡和IL-1 β诱导过程中的作用，因为它与血管炎症和动脉粥样硬化有关，以便找到新的和更有效的方法来预防和治疗这种疾病。我们将操纵线粒体DNA修复系统，以研究其作为一种新的治疗策略的潜力，该策略将防止IL-1 β（以及IL-18-另一种NLRP 3依赖性细胞因子）的激活，而不是目前的策略，在IL-1 β已经释放并导致下游激活后中和IL-1 β。基于这些关键发现，我们提出了以下两个目标，重点围绕中心假设，即在血管炎症过程中发生的氧化mtDNA损伤激活NLRP 3炎性小体产生IL-1 β，并在动脉粥样硬化形成中发挥促炎作用。抑制氧化性DNA损伤将防止NLRP 3炎性体活化并导致血管炎症和动脉粥样硬化减少。具体目的1-使用DNA损伤修复基因Ogg 1缺陷的小鼠，确定在饮食诱导的高胆固醇血症小鼠动脉粥样硬化模型中NLRP 3炎性小体激活期间线粒体DNA损伤的作用。目的2-研究通过合成8-OH-dG给药阻断线粒体DNA诱导的NLRP 3激活的治疗作用，并确定Ogg 1基因转移增强Mt DNA修复的作用。